JP2019513010A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513010A5 JP2019513010A5 JP2018546415A JP2018546415A JP2019513010A5 JP 2019513010 A5 JP2019513010 A5 JP 2019513010A5 JP 2018546415 A JP2018546415 A JP 2018546415A JP 2018546415 A JP2018546415 A JP 2018546415A JP 2019513010 A5 JP2019513010 A5 JP 2019513010A5
- Authority
- JP
- Japan
- Prior art keywords
- muscle
- composition
- injury
- atrophy
- muscle injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000029549 Muscle injury Diseases 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 19
- 201000000585 muscular atrophy Diseases 0.000 claims 7
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 claims 6
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 claims 6
- 206010028289 Muscle atrophy Diseases 0.000 claims 6
- 230000020763 muscle atrophy Effects 0.000 claims 6
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 4
- 210000002027 skeletal muscle Anatomy 0.000 claims 4
- 206010006895 Cachexia Diseases 0.000 claims 3
- 102100028207 6-phosphogluconate dehydrogenase, decarboxylating Human genes 0.000 claims 2
- 101710151348 D-3-phosphoglycerate dehydrogenase Proteins 0.000 claims 2
- 208000010428 Muscle Weakness Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 206010028372 Muscular weakness Diseases 0.000 claims 2
- 201000009623 Myopathy Diseases 0.000 claims 2
- 208000026214 Skeletal muscle atrophy Diseases 0.000 claims 2
- 102100027187 Solute carrier organic anion transporter family member 2A1 Human genes 0.000 claims 2
- 201000009338 distal myopathy Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 230000003472 neutralizing effect Effects 0.000 claims 2
- 230000025185 skeletal muscle atrophy Effects 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 108010038663 Hydroxyprostaglandin Dehydrogenases Proteins 0.000 claims 1
- 102000010817 Hydroxyprostaglandin Dehydrogenases Human genes 0.000 claims 1
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010039020 Rhabdomyolysis Diseases 0.000 claims 1
- 108091006791 SLCO2A1 Proteins 0.000 claims 1
- 208000026137 Soft tissue injury Diseases 0.000 claims 1
- 101710095536 Solute carrier organic anion transporter family member 2A1 Proteins 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 1
- 229960002986 dinoprostone Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000006913 intermediate spinal muscular atrophy Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000011866 long-term treatment Methods 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 230000003274 myotonic effect Effects 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 210000005239 tubule Anatomy 0.000 claims 1
- 208000032521 type II spinal muscular atrophy Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022089405A JP2022116259A (ja) | 2016-03-04 | 2022-06-01 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
| JP2024098418A JP2024116386A (ja) | 2016-03-04 | 2024-06-19 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662303979P | 2016-03-04 | 2016-03-04 | |
| US62/303,979 | 2016-03-04 | ||
| US201662348116P | 2016-06-09 | 2016-06-09 | |
| US62/348,116 | 2016-06-09 | ||
| PCT/US2017/020650 WO2017152044A1 (en) | 2016-03-04 | 2017-03-03 | Compositions and methods for muscle regeneration using prostaglandin e2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022089405A Division JP2022116259A (ja) | 2016-03-04 | 2022-06-01 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513010A JP2019513010A (ja) | 2019-05-23 |
| JP2019513010A5 true JP2019513010A5 (enExample) | 2020-04-09 |
Family
ID=59743257
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546415A Withdrawn JP2019513010A (ja) | 2016-03-04 | 2017-03-03 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
| JP2022089405A Pending JP2022116259A (ja) | 2016-03-04 | 2022-06-01 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
| JP2024098418A Pending JP2024116386A (ja) | 2016-03-04 | 2024-06-19 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022089405A Pending JP2022116259A (ja) | 2016-03-04 | 2022-06-01 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
| JP2024098418A Pending JP2024116386A (ja) | 2016-03-04 | 2024-06-19 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240415849A1 (enExample) |
| EP (2) | EP4538365A3 (enExample) |
| JP (3) | JP2019513010A (enExample) |
| KR (2) | KR102387896B1 (enExample) |
| CN (2) | CN109072186B (enExample) |
| AU (3) | AU2017225999B2 (enExample) |
| CA (1) | CA3014667A1 (enExample) |
| DK (1) | DK3423067T3 (enExample) |
| ES (1) | ES3039622T3 (enExample) |
| WO (1) | WO2017152044A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9918994B2 (en) | 2016-03-04 | 2018-03-20 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin E2 |
| US10159566B2 (en) * | 2016-09-26 | 2018-12-25 | Novartis Ag | Heat tunable intraocular lens |
| JP7595413B2 (ja) | 2016-11-30 | 2024-12-06 | ケース ウエスタン リザーブ ユニバーシティ | １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用 |
| WO2018145080A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| CN110891568A (zh) | 2017-04-07 | 2020-03-17 | 凯斯西储大学 | 用于治疗冠状动脉病症的短链脱氢酶活性的抑制剂 |
| AU2018280264B2 (en) | 2017-06-09 | 2024-07-11 | Myoforte Therapeutics, Inc. | Compositions and methods for preventing or treating muscle conditions |
| PE20212246A1 (es) | 2018-11-21 | 2021-11-24 | Univ Case Western Reserve | Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta |
| JP2022530232A (ja) * | 2019-04-30 | 2022-06-28 | パエアン バイオテクノロジー インコーポレイテッド | 活性成分として単離されたミトコンドリアを含む、筋炎を予防又は治療するための医薬組成物 |
| KR20220019760A (ko) * | 2019-06-11 | 2022-02-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 15-하이드록시프로스타글란딘 데하이드로게나제(15-pgdh)를 억제하여 노화된 조직을 젊어지게 하는 방법 |
| JP2022547620A (ja) * | 2019-09-16 | 2022-11-14 | インスティテュート オブ ズーオロジー、チャイニーズ アカデミー オブ サイエンシーズ | 組織再生のための方法及び組成物 |
| US20230210829A1 (en) * | 2020-06-11 | 2023-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Rejuvenation of aged tissues by inhibition of the pge2 degrading enzyme, 15-pgdh |
| US20240000758A1 (en) * | 2020-10-23 | 2024-01-04 | The Board Of Trustees Of The Leland Stanford Junior University | Elevation of mitochondrial biogenesis and function by inhibition of prostaglandin degrading enzyme 15-pgdh |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3927213A (en) * | 1973-07-10 | 1975-12-16 | American Home Prod | Prostaglandin E{HD 2 {B and derivatives for reducing the side effects of anti-inflammatory agents |
| US5143842A (en) | 1988-11-01 | 1992-09-01 | The University Of Colorado Foundation, Inc. | Media for normal human muscle satellite cells |
| US5409911A (en) | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
| US5833978A (en) * | 1995-03-16 | 1998-11-10 | Universite Laval | Method of in vitro preconditioning healthy donor's myoblasts before transplantation thereof in compatible patients suffering of recessive myopathies like muscular dystrophy, for improving transplantation success |
| EP1132086B1 (en) | 2000-01-31 | 2006-05-31 | Pfizer Products Inc. | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure |
| SK5562003A3 (en) * | 2000-11-27 | 2004-08-03 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis |
| US6410591B1 (en) | 2001-05-08 | 2002-06-25 | Allergan Sales, Inc. | 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| EP1417975B1 (en) | 2001-07-23 | 2011-03-02 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
| US6841573B2 (en) * | 2002-11-27 | 2005-01-11 | Molecular Nutrition | Use of arachidonic acid as a method of increasing skeletal muscle mass |
| US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
| US7169807B2 (en) | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
| US20080234337A1 (en) * | 2004-08-10 | 2008-09-25 | Ono Pharmaceutical Co., Ltd. | Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist |
| US7696235B2 (en) | 2005-08-29 | 2010-04-13 | Allergan, Inc. | EP2 receptor agonists for treating glaucoma |
| PE20071230A1 (es) | 2006-02-09 | 2008-01-16 | Schering Corp | Combinaciones y metodos de inhibidores del vhc |
| RU2425876C2 (ru) * | 2006-03-24 | 2011-08-10 | Чилдрен'З Медикал Сентер Корпорейшн | Способ модулирования роста гематопоэтических стволовых клеток |
| EA200970067A1 (ru) | 2006-07-28 | 2009-08-28 | Пфайзер Продактс Инк. | Агонисты ep2 |
| CA2706879A1 (en) | 2007-11-29 | 2009-06-11 | Robert M. Burk | Substituted cyclopentanes having prostaglandin activity |
| US8871752B2 (en) * | 2008-02-19 | 2014-10-28 | Sucampo Ag | Method for modulating stem cell growth |
| EP2272948A4 (en) | 2008-04-11 | 2012-08-08 | Univ Keio | METHOD OF INSULATING A SMOOTH MUSCLE STEM CELL |
| EP2637702A4 (en) * | 2010-11-11 | 2014-11-26 | Univ Miami | METHODS, COMPOSITIONS, CELLS AND KITS FOR TREATING ISCHEMIC INJURIES |
| EP2785350B1 (en) * | 2011-12-02 | 2018-05-02 | Fate Therapeutics, Inc. | Improved methods of treating ischemia |
| EP3295940A1 (en) * | 2012-04-16 | 2018-03-21 | Case Western Reserve University | Compositions and methods of modulating 15-pgdh activity |
| US20130331389A1 (en) * | 2012-06-11 | 2013-12-12 | National Cheng Kung University | Methods and Compositions for Cardiomyocyte Replenishment by Endogenous and Progenitor Stem Cells |
| EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| CA2927730A1 (en) * | 2013-10-15 | 2015-05-07 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
-
2017
- 2017-03-03 JP JP2018546415A patent/JP2019513010A/ja not_active Withdrawn
- 2017-03-03 EP EP24220295.0A patent/EP4538365A3/en active Pending
- 2017-03-03 EP EP17760893.2A patent/EP3423067B1/en active Active
- 2017-03-03 DK DK17760893.2T patent/DK3423067T3/da active
- 2017-03-03 KR KR1020187028393A patent/KR102387896B1/ko active Active
- 2017-03-03 WO PCT/US2017/020650 patent/WO2017152044A1/en not_active Ceased
- 2017-03-03 KR KR1020227012174A patent/KR102481354B1/ko active Active
- 2017-03-03 ES ES17760893T patent/ES3039622T3/es active Active
- 2017-03-03 AU AU2017225999A patent/AU2017225999B2/en active Active
- 2017-03-03 CN CN201780014836.9A patent/CN109072186B/zh active Active
- 2017-03-03 CN CN202310631766.9A patent/CN116716241A/zh active Pending
- 2017-03-03 CA CA3014667A patent/CA3014667A1/en active Pending
-
2022
- 2022-06-01 JP JP2022089405A patent/JP2022116259A/ja active Pending
- 2022-11-10 AU AU2022268368A patent/AU2022268368B2/en active Active
-
2024
- 2024-03-25 US US18/615,080 patent/US20240415849A1/en active Pending
- 2024-06-19 JP JP2024098418A patent/JP2024116386A/ja active Pending
- 2024-12-04 US US18/968,148 patent/US20250090549A1/en active Pending
- 2024-12-18 AU AU2024278535A patent/AU2024278535A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513010A5 (enExample) | ||
| JP2015502974A5 (enExample) | ||
| JP2016510769A5 (enExample) | ||
| JP2022068329A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2019094345A5 (enExample) | ||
| PH12015502012A1 (en) | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | |
| JP2017537940A5 (enExample) | ||
| JP2014530818A5 (enExample) | ||
| JPWO2020123827A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2018108086A5 (enExample) | ||
| JP2011527333A5 (enExample) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2010505865A5 (enExample) | ||
| MY207696A (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| JP2008546770A5 (enExample) | ||
| RU2013155509A (ru) | Применение ингибирования катепсина к для лечения и/или профилактики легочной гипертензии и/или сердечной недостаточности | |
| JPWO2023099592A5 (enExample) | ||
| MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
| JPWO2023195529A5 (enExample) | ||
| JPWO2021151014A5 (enExample) | ||
| JP2011046708A5 (enExample) | ||
| ZA202106097B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof | |
| JP2024009799A5 (enExample) |